Clinical Trial Update: VYxeoS Liposomal Italian Observational Study iN the Real Practice

View source ↗

Summary

A real-world observational study in Italy evaluating Vyxeos (CPX-351) for acute myeloid leukemia and its subtypes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Myelodysplasia-related Changes
• Therapy-related Acute Myeloid Leukemia

Drugs mentioned

• Vyxeos (CPX-351)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Status: COMPLETED